NCT04429555View on ClinicalTrials.gov

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

August 7, 2024

Conditions
Pneumonia, Viral
Interventions
DRUG

Ibudilast

50 mg (5 x 10 mg capsules) twice daily for 7 days

DRUG

Placebo

0 mg (5 matching capsules) twice daily for 7 days

Trial Locations (2)

80204

Denver Health and Hospital Authority, Denver

06520

Yale University School of Medicine, New Haven

Sponsors

Lead Sponsor

MediciNova
All Listed Sponsors
lead

MediciNova

INDUSTRY

NCT04429555 - Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS | Biotech Hunter | Biotech Hunter